Literature DB >> 20101094

Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.

So Yeon Park1, Mithat Gönen, Hee Jung Kim, Franziska Michor, Kornelia Polyak.   

Abstract

Intratumor genetic heterogeneity is a key mechanism underlying tumor progression and therapeutic resistance. The prevailing model for explaining intratumor diversity, the clonal evolution model, has recently been challenged by proponents of the cancer stem cell hypothesis. To investigate this issue, we performed combined analyses of markers associated with cellular differentiation states and genotypic alterations in human breast carcinomas and evaluated diversity with ecological and evolutionary methods. Our analyses showed a high degree of genetic heterogeneity both within and between distinct tumor cell populations that were defined based on markers of cellular phenotypes including stem cell-like characteristics. In several tumors, stem cell-like and more-differentiated cancer cell populations were genetically distinct, leading us to question the validity of a simple differentiation hierarchy-based cancer stem cell model. The degree of diversity correlated with clinically relevant breast tumor subtypes and in some tumors was markedly different between the in situ and invasive cell populations. We also found that diversity measures were associated with clinical variables. Our findings highlight the importance of genetic diversity in intratumor heterogeneity and the value of analyzing tumors as distinct populations of cancer cells to more effectively plan treatments.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101094      PMCID: PMC2810089          DOI: 10.1172/JCI40724

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.

Authors:  So Yeon Park; Hee Eun Lee; Hailun Li; Michail Shipitsin; Rebecca Gelman; Kornelia Polyak
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

2.  Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient.

Authors:  M Gönen; K S Panageas; S M Larson
Journal:  Radiology       Date:  2001-12       Impact factor: 11.105

3.  Tumor heterogeneity: biological implications and therapeutic consequences.

Authors:  G H Heppner; B E Miller
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

Review 4.  Mammary tumor heterogeneity.

Authors:  G H Heppner; S E Loveless; F R Miller; K H Mahoney; A M Fulton
Journal:  Symp Fundam Cancer Res       Date:  1983

5.  Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.

Authors:  Wolf-Karsten Hofmann; Martina Komor; Barbara Wassmann; Letetia C Jones; Harald Gschaidmeier; Dieter Hoelzer; H Phillip Koeffler; Oliver G Ottmann
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

6.  Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.

Authors:  Christoph A Klein; Thomas J F Blankenstein; Oleg Schmidt-Kittler; Marco Petronio; Bernhard Polzer; Nikolas H Stoecklein; Gert Riethmüller
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

7.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Authors:  Catherine Roche-Lestienne; Valerie Soenen-Cornu; Nathalie Grardel-Duflos; Jean-Luc Laï; Nathalie Philippe; Thierry Facon; Pierre Fenaux; Claude Preudhomme
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

8.  Purification of the human NF-E2 complex: cDNA cloning of the hematopoietic cell-specific subunit and evidence for an associated partner.

Authors:  P A Ney; N C Andrews; S M Jane; B Safer; M E Purucker; S Weremowicz; C C Morton; S C Goff; S H Orkin; A W Nienhuis
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

9.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.

Authors:  N Konishi; Y Hiasa; H Matsuda; M Tao; T Tsuzuki; I Hayashi; Y Kitahori; T Shiraishi; R Yatani; J Shimazaki
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

10.  Metapopulation dynamics and spatial heterogeneity in cancer.

Authors:  Isabel González-García; Ricard V Solé; José Costa
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-26       Impact factor: 11.205

View more
  173 in total

Review 1.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

2.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Authors:  Lauren L C Marotta; Vanessa Almendro; Andriy Marusyk; Michail Shipitsin; Janina Schemme; Sarah R Walker; Noga Bloushtain-Qimron; Jessica J Kim; Sibgat A Choudhury; Reo Maruyama; Zhenhua Wu; Mithat Gönen; Laura A Mulvey; Marina O Bessarabova; Sung Jin Huh; Serena J Silver; So Young Kim; So Yeon Park; Hee Eun Lee; Karen S Anderson; Andrea L Richardson; Tatiana Nikolskaya; Yuri Nikolsky; X Shirley Liu; David E Root; William C Hahn; David A Frank; Kornelia Polyak
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 3.  The influence of subclonal resistance mutations on targeted cancer therapy.

Authors:  Michael W Schmitt; Lawrence A Loeb; Jesse J Salk
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 4.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

5.  Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia.

Authors:  Amy L Paguirigan; Jordan Smith; Soheil Meshinchi; Martin Carroll; Carlo Maley; Jerald P Radich
Journal:  Sci Transl Med       Date:  2015-04-01       Impact factor: 17.956

6.  Long-term cultures of stem/progenitor cells from lobular and ductal breast carcinomas under non-adherent conditions.

Authors:  Agostina Nardone; Sara Corvigno; Annalisa Brescia; Daniel D'Andrea; Gennaro Limite; Bianca Maria Veneziani
Journal:  Cytotechnology       Date:  2010-12-28       Impact factor: 2.058

7.  Accurate reconstruction of the temporal order of mutations in neoplastic progression.

Authors:  Kathleen Sprouffske; John W Pepper; Carlo C Maley
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-13

8.  Tumor evolution in response to chemotherapy: phenotype versus genotype.

Authors:  Nicholas E Navin
Journal:  Cell Rep       Date:  2014-02-13       Impact factor: 9.423

9.  Selection and adaptation during metastatic cancer progression.

Authors:  Christoph A Klein
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

10.  Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.

Authors:  Vanessa Almendro; Yu-Kang Cheng; Amanda Randles; Shalev Itzkovitz; Andriy Marusyk; Elisabet Ametller; Xavier Gonzalez-Farre; Montse Muñoz; Hege G Russnes; Aslaug Helland; Inga H Rye; Anne-Lise Borresen-Dale; Reo Maruyama; Alexander van Oudenaarden; Mitchell Dowsett; Robin L Jones; Jorge Reis-Filho; Pere Gascon; Mithat Gönen; Franziska Michor; Kornelia Polyak
Journal:  Cell Rep       Date:  2014-01-23       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.